IMR Press / FBL / Volume 28 / Issue 9 / DOI: 10.31083/j.fbl2809212
Open Access Original Research
SPI1-Mediated Upregulation of the CST1 Gene as an Independent Poor Prognostic Factor Accelerates Metastasis in Esophageal Squamous Cell Carcinoma (ESCC) by Interacting with MMP2
Show Less
1 Department of Experimental Research, State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 510060 Guangzhou, Guangdong, China
2 Department of Cardiothoracic Surgery, Zhongshan People's Hospital, 529403 Zhongshan, Guangdong, China
3 Department of Radiation Oncology, People's Hospital of Guangxi Zhuang Autonomous Region, 530021 Nanning, Guangxi, China
4 Department of Nuclear Medicine, The Second People’s Hospital of Shenzhen, 518035 Shenzhen, Guangdong, China
5 Department of Clinical Medical Research Institute, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asian, The First Affiliated Hospital of Xinjiang Medical University, 830011 Urumqi, Xinjiang, China
6 Department of Oncology, The People's Hospital of Gaozhou, 6664126 Gaozhou, Guangdong, China
*Correspondence: yangchfu2013@163.com (Chang-Fu Yang); huangbj@sysucc.org.cn (Bi-Jun Huang)
These authors contributed equally.
Front. Biosci. (Landmark Ed) 2023, 28(9), 212; https://doi.org/10.31083/j.fbl2809212
Submitted: 11 January 2023 | Revised: 9 March 2023 | Accepted: 4 April 2023 | Published: 24 September 2023
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Background: Esophageal squamous cell carcinoma (ESCC) is a highly lethal tumor type, but studies on the ESCC tumor microenvironment are limited. We found that cystatin SN (CST1) plays an important role in the ESCC tumor microenvironment. CST1 has been reported to act as an oncogene in multiple human cancers, but its clinical significance and underlying mechanism in ESCC remain elusive. Methods: We performed ESCC gene expression profiling with data from RNA-sequencing and public databases and found CST1 upregulation in ESCC. Then, we assessed CST1 expression in ESCC by RT‒qPCR and Western blot analysis. In addition, immunohistochemistry (IHC) and enzyme-linked immunosorbent assay (ELISA) were used to estimate the expression of CST1 in ESCC tissue and serum. Moreover, further functional experiments were conducted to verify that the gain and loss of CST1 in ESCC cell lines significantly influenced the proliferation and metastasis of ESCC. Mass spectrometry, coimmunoprecipitation, and gelatin zymography experiments were used to validate the interaction between CST1 and matrix metalloproteinase 2 (MMP2) and the mechanism of CST1 influence on metastasis in ESCC. Results: Here, we found that CST1 expression was significantly elevated in ESCC tissues and serum. Moreover, compared with patients with low CST1 expression, patients with high CST1 expression had a worse prognosis. Overall survival (OS) and disease-free survival (DFS) were significantly unfavorable in the high CST1 expression subgroup. Likewise, the CST1 level was significantly increased in ESCC serum compared with healthy control serum, indicating that CST1 may be a potential serum biomarker for diagnosis, with an area under the curve (AUC) = 0.9702 and p < 0.0001 by receiver operating curve (ROC) analysis. Furthermore, upregulated CST1 can promote the motility and metastatic capacity of ESCC in vitro and in vivo by influencing epithelial mesenchymal transition (EMT) and interacting with MMP2 in the tumor microenvironment (TME). Conclusions: Collectively, the results of this study indicated that high CST1 expression mediated by SPI1 in ESCC may serve as a potentially prognostic and diagnostic predictor and as an oncogene to promote motility and metastatic capacity of ESCC by influencing EMT and interacting with MMP2 in the TME.

Keywords
CST1
esophageal squamous cell carcinoma (ESCC)
metastasis
prognostic biomarker
tumor microenvironment (TME)
matrix metalloproteinase (MMP)
Funding
81972785/National Natural Science Foundation of China
81773162/National Natural Science Foundation of China
81572901/National Natural Science Foundation of China
2017A030313866/Provincial Natural Science Foundation of Guangdong
2017A030313866/Provincial Natural Science Foundation of Guangdong
HN2021-09/Open Funds of State Key Laboratory of Oncology in South China
Figures
Fig. 1.
Share
Back to top